Clinical Trial Update: Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of Phase 1/2 clinical trials evaluating ranibizumab for recalcitrant wet age-related macular degeneration in eyes previousl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Northern California Retina Vitreous Associates | Conditions: Recalcitrant Wet Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED